Feasibility of Innovative Approaches for Personalized Cardiovascular Prevention
NCT ID: NCT06911294
Last Updated: 2025-08-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
120 participants
INTERVENTIONAL
2025-02-10
2026-09-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Feasibility of a greater study.
* Feasibility of the interventions in a realistic setting, such as the medical office of a General Practitioner.
Participants will be randomized in one of the four parallel arms:
* standard of care;
* genetic testing for cardiovascular genetic risk (through the cardiovascular Polygenic Risk Score or PRS);
* digital intervention with a wearable device and its app;
* digital intervention and genetic testing
The primary outcomes that are going to be evaluated are patient's and General Practitioners' overall judgment of the study and its feasibility.
Secondarily the efficacy of returning Polygenic Risk Score (PRS) results will be assessed. This will happen on two endpoints: i) change in lifestyle pattern; ii) CVD risk profile modification. The postulated hypothesis is that the achievement of these endpoints is more likely in presence of at least one of the aforementioned interventions than among subjects who receive only traditional risk assessment at baseline.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Novel Risk Prediction Approaches for the Primary Prevention of Cardiovascular Diseases in Italy: the CVRISK-IT Trial (CVRISK-IT)
NCT06832644
Perception of Cardiovascular Risk
NCT06190743
The Cardiovascular Prevention Program
NCT06362538
Preventive Health Practices in Women
NCT00724399
Denver Health Cardiovascular Disease (CVD) Prevention Program
NCT00829491
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The enrollment period will last 6 months, with each participant taking part in the study for 12. There are three key time points in the study, T0 or baseline (enrollment phase), T1 or disclosure visit after one month, T2 intermediate visit(after six months) and T3 or final visit at 12 months. At enrollment, participants will be classified into risk categories based on cardiovascular risk using the SCORE-2 or SCORE 2-OP tool. Individuals aged 40-69, without diabetes or congenital hypercolesterolemia, with a SCORE-2 between 2.5% and 10% and a diagnosys of metabolic syndrome according to the American Hearth Association Criteria will be enrolled.
Once enrolled (T0), all participants will sign the informed consent form and undergo a comprehensive assessment, which includes:
* Completing a questionnaire on socioeconomic status, area of residence, and lifestyle, using the Life's Essential 8 tool. The questionnaire will cover smoking status, alcohol consumption, dietary pattern, sleep pattern, and physical activity. Participants will be classified into favorable, intermediate, or unfavorable individual lifestyle patterns according to the Life's Essential 8 score.
* Blood analysis will be performed to evaluate the lipid profile, including total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides.
At T1, a disclosure visit will be conducted to explain the assigned lifestyle category, share the results of the blood tests, and provide information on the expected interventions based on the assigned group.
The questionnaire will be administered at T0, T2, and T3. Blood analysis and cardiovascular profile evaluation will be conducted at both T0 and T3.
Feasibility Questionnaire: Both participants and medical professionals will complete a questionnaire on the acceptability and feasibility of the intervention.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
No intervention - Standard of Care
Participants will receive traditional lifestyle advices in order to reduce the risk.
No interventions assigned to this group
Genetic testing - PRS
Arm Description: Participants will receive the information of the genetic cardiovascular risk (PRS) and personalized advices.
Polygenic Risk Score
genetic test for the evaluation of cardiovascular risk
Experimental: Digital intervention - app and wearable device
Arm Description: Participants will receive an app and a wearable device for the evaluation of various parameters.
Digital app and wearable device
a wearable device connected with its app
Digital intervention and genetic testing - PRS
Arm Description: Participants will receive both app and wearable device and PRS information
Polygenic Risk Score
genetic test for the evaluation of cardiovascular risk
Digital app and wearable device
a wearable device connected with its app
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Polygenic Risk Score
genetic test for the evaluation of cardiovascular risk
Digital app and wearable device
a wearable device connected with its app
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 10 year cardiovascular risk score SCORE2 between 2.5% and 10%.
* Diagnosis of metabolic syndrome according to the American Heart Association criteria , defined as the presence of three or more of the following:
* Central or abdominal obesity, measured by waist circumference (greater than 40 inches - 102 cm in men and 35 inches - 89 cm in women).
* Elevated triglycerides: levels equal to or greater than 150 mg/dL or use of medication for hypertriglyceridemia.
* Low HDL cholesterol levels (less than 40 mg/dL in men and less than 50 mg/dL in women) or use of cholesterol-lowering medication.
* Elevated blood pressure: systolic ≥130 mmHg or diastolic ≥85 mmHg, or use of antihypertensive medication.
* Elevated fasting blood glucose: ≥100 mg/dL or use of glucose-lowering medication.
Exclusion Criteria
* Familial hypercholesterolemia;
* Previous cardiovascular events.
40 Years
69 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Catholic University of the Sacred Heart
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Roberta Pastorino
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Studio Antonaci
Rome, Italy, Italy
Studio Colletti
Rome, , Italy
Studio Maggiori
Rome, , Italy
Studio Mammucari
Rome, , Italy
Studio Marra
Rome, , Italy
Studio Paoletti
Rome, , Italy
Studio Pasca
Rome, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Lloyd-Jones DM, Allen NB, Anderson CAM, Black T, Brewer LC, Foraker RE, Grandner MA, Lavretsky H, Perak AM, Sharma G, Rosamond W; American Heart Association. Life's Essential 8: Updating and Enhancing the American Heart Association's Construct of Cardiovascular Health: A Presidential Advisory From the American Heart Association. Circulation. 2022 Aug 2;146(5):e18-e43. doi: 10.1161/CIR.0000000000001078. Epub 2022 Jun 29.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
7700, 7885-7890
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.